AdultPediatricGeriatricDosage Forms & Strengths tablet: Schedule IV 250mg 350mg Musculoskeletal Conditions 250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritability Dosing Modifications Renal impairment: Caution; not studied Hepatic impairment: Caution; not studiedDosage Forms & Strengths tablet: Schedule IV 250mg 350mg Musculoskeletal Conditions <16 years: Not recommended >16 years: 250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritabilityNot drug of choice in elderly, owing to risk of orthostatic hypotension and CNS depressionInteraction CheckerEnter a drug name and carisoprodolNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (13)apalutamideapalutamide will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine subdermal implantbuprenorphine subdermal implant and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and carisoprodol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecalcium/magnesium/potassium/sodium oxybatescarisoprodol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydrocodonehydrocodone, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.lonafarniblonafarnib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.metoclopramide intranasalcarisoprodol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olopatadine intranasalcarisoprodol and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. selinexorselinexor, carisoprodol. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybatecarisoprodol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.Monitor Closely (172)abobotulinumtoxinAcarisoprodol increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.acrivastineacrivastine and carisoprodol both increase sedation. Use Caution/Monitor.alfentanilcarisoprodol and alfentanil both increase sedation. Use Caution/Monitor.alprazolamalprazolam and carisoprodol both increase sedation. Use Caution/Monitor.amisulprideamisulpride and carisoprodol both increase sedation. Use Caution/Monitor.amitriptylinecarisoprodol and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and carisoprodol both increase sedation. Use Caution/Monitor.amoxapinecarisoprodol and amoxapine both increase sedation. Use Caution/Monitor.apomorphinecarisoprodol and apomorphine both increase sedation. Use Caution/Monitor.aripiprazolecarisoprodol and aripiprazole both increase sedation. Use Caution/Monitor.asenapineasenapine and carisoprodol both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and carisoprodol both increase sedation. Use Caution/Monitor.avapritinibavapritinib and carisoprodol both increase sedation. Use Caution/Monitor.azelastineazelastine and carisoprodol both increase sedation. Use Caution/Monitor.baclofenbaclofen and carisoprodol both increase sedation. Use Caution/Monitor.belladonna and opiumcarisoprodol and belladonna and opium both increase sedation. Use Caution/Monitor.benperidolcarisoprodol and benperidol both increase sedation. Use Caution/Monitor.benzphetaminecarisoprodol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.brexanolonebrexanolone, carisoprodol. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and carisoprodol both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and carisoprodol both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and carisoprodol both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.buprenorphinecarisoprodol and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccalcarisoprodol and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionbuprenorphine, long-acting injection increases effects of carisoprodol by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.butabarbitalbutabarbital and carisoprodol both increase sedation. Use Caution/Monitor.butalbitalbutalbital and carisoprodol both increase sedation. Use Caution/Monitor.butorphanolcarisoprodol and butorphanol both increase sedation. Use Caution/Monitor.cannabidiolcannabidiol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. carbinoxaminecarbinoxamine and carisoprodol both increase sedation. Use Caution/Monitor.cenobamatecenobamate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate. cenobamate, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and carisoprodol both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and carisoprodol both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.chlorpromazinecarisoprodol and chlorpromazine both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and carisoprodol both increase sedation. Use Caution/Monitor.clemastineclemastine and carisoprodol both increase sedation. Use Caution/Monitor.clobazamcarisoprodol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminecarisoprodol and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and carisoprodol both increase sedation. Use Caution/Monitor.clorazepateclorazepate and carisoprodol both increase sedation. Use Caution/Monitor.clozapinecarisoprodol and clozapine both increase sedation. Use Caution/Monitor.codeinecarisoprodol and codeine both increase sedation. Use Caution/Monitor.cyclizinecyclizine and carisoprodol both increase sedation. Use Caution/Monitor.cyclobenzaprinecarisoprodol and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and carisoprodol both increase sedation. Use Caution/Monitor.dantrolenecarisoprodol and dantrolene both increase sedation. Use Caution/Monitor.daridorexantcarisoprodol and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. desipraminecarisoprodol and desipramine both increase sedation. Use Caution/Monitor.dexchlorpheniraminedexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.dexfenfluraminecarisoprodol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidinedexmedetomidine and carisoprodol both increase sedation. Use Caution/Monitor.dextromoramidecarisoprodol and dextromoramide both increase sedation. Use Caution/Monitor.diamorphinecarisoprodol and diamorphine both increase sedation. Use Caution/Monitor.diazepamdiazepam and carisoprodol both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.difelikefalindifelikefalin and carisoprodol both increase sedation. Use Caution/Monitor.difenoxin hclcarisoprodol and difenoxin hcl both increase sedation. Use Caution/Monitor.dimenhydrinatedimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and carisoprodol both increase sedation. Use Caution/Monitor.diphenoxylate hclcarisoprodol and diphenoxylate hcl both increase sedation. Use Caution/Monitor.dipipanonecarisoprodol and dipipanone both increase sedation. Use Caution/Monitor.dopexaminecarisoprodol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepincarisoprodol and dosulepin both increase sedation. Use Caution/Monitor.doxepincarisoprodol and doxepin both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and carisoprodol both increase sedation. Use Caution/Monitor.droperidolcarisoprodol and droperidol both increase sedation. Use Caution/Monitor.elagolixelagolix will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.esketamine intranasalesketamine intranasal, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateeslicarbazepine acetate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.estazolamestazolam and carisoprodol both increase sedation. Use Caution/Monitor.ethanolcarisoprodol and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and carisoprodol both increase sedation. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fenfluraminecarisoprodol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fexinidazolefexinidazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fluphenazinecarisoprodol and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and carisoprodol both increase sedation. Use Caution/Monitor.ganaxolonecarisoprodol and ganaxolone both increase sedation. Use Caution/Monitor.haloperidolcarisoprodol and haloperidol both increase sedation. Use Caution/Monitor.hydromorphonecarisoprodol and hydromorphone both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and carisoprodol both increase sedation. Use Caution/Monitor.iloperidonecarisoprodol and iloperidone both increase sedation. Use Caution/Monitor.imipraminecarisoprodol and imipramine both increase sedation. Use Caution/Monitor.incobotulinumtoxinAcarisoprodol, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.ketamineketamine and carisoprodol both increase sedation. Use Caution/Monitor.ketotifen, ophthalmiccarisoprodol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lasmiditanlasmiditan, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantlemborexant, carisoprodol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levorphanolcarisoprodol and levorphanol both increase sedation. Use Caution/Monitor.lofepraminecarisoprodol and lofepramine both increase sedation. Use Caution/Monitor.lofexidinecarisoprodol and lofexidine both increase sedation. Use Caution/Monitor.loprazolamloprazolam and carisoprodol both increase sedation. Use Caution/Monitor.lorazepamlorazepam and carisoprodol both increase sedation. Use Caution/Monitor.lormetazepamlormetazepam and carisoprodol both increase sedation. Use Caution/Monitor.loxapinecarisoprodol and loxapine both increase sedation. Use Caution/Monitor.loxapine inhaledcarisoprodol and loxapine inhaled both increase sedation. Use Caution/Monitor.lumacaftor/ivacaftorlumacaftor/ivacaftor, carisoprodol. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .lurasidonelurasidone, carisoprodol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilinecarisoprodol and maprotiline both increase sedation. Use Caution/Monitor.marijuanacarisoprodol and marijuana both increase sedation. Use Caution/Monitor.melatonincarisoprodol and melatonin both increase sedation. Use Caution/Monitor.meperidinecarisoprodol and meperidine both increase sedation. Use Caution/Monitor.meprobamatecarisoprodol and meprobamate both increase sedation. Use Caution/Monitor.metaxalonecarisoprodol and metaxalone both increase sedation. Use Caution/Monitor.methadonecarisoprodol and methadone both increase sedation. Use Caution/Monitor.methocarbamolcarisoprodol and methocarbamol both increase sedation. Use Caution/Monitor.methylenedioxymethamphetaminecarisoprodol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.midazolammidazolam and carisoprodol both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.mirtazapinecarisoprodol and mirtazapine both increase sedation. Use Caution/Monitor.morphinecarisoprodol and morphine both increase sedation. Use Caution/Monitor.motherwortcarisoprodol and motherwort both increase sedation. Use Caution/Monitor.moxonidinecarisoprodol and moxonidine both increase sedation. Use Caution/Monitor.nabilonecarisoprodol and nabilone both increase sedation. Use Caution/Monitor.nalbuphinecarisoprodol and nalbuphine both increase sedation. Use Caution/Monitor.nortriptylinecarisoprodol and nortriptyline both increase sedation. Use Caution/Monitor.olanzapinecarisoprodol and olanzapine both increase sedation. Use Caution/Monitor.oliceridineoliceridine, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation,